Literature DB >> 26961871

Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.

Vittorio Caropreso1, Emad Darvishi1, Thomas J Turbyville2, Ranjala Ratnayake1, Patrick J Grohar3, James B McMahon1, Girma M Woldemichael4.   

Abstract

High-throughput screening of extracts from plants, marine, and micro-organisms led to the identification of the extract from the plant Phyllanthus engleri as the most potent inhibitor of EWS-FLI1 induced luciferase reporter expression. Testing of compounds isolated from this extract in turn led to the identification of Englerin A (EA) as the active constituent of the extract. EA induced both necrosis and apoptosis in Ewing cells subsequent to a G2M accumulation of cells in the cell cycle. It also impacted clonogenic survival and anchorage-independent proliferation while also decreasing the proportion of chemotherapy-resistant cells identified by high ALDH activity. EA also caused a sustained increase in cytosolic calcium levels. EA appears to exert its effect on Ewing cells through a decrease in phosphorylation of EWS-FLI1 and its ability to bind DNA. This effect is mediated, at least in part, through a decrease in the levels of the calcium-dependent protein kinase PKC-βI after a transient up-regulation.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  DNA-binding protein; EWS-FLI1; Englerin A; Ewings sarcoma; calcium; inhibition mechanism; inhibitor; transcription factor

Mesh:

Substances:

Year:  2016        PMID: 26961871      PMCID: PMC4858959          DOI: 10.1074/jbc.M115.701375

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Marine natural products as targeted modulators of the transcription factor NF-kappaB.

Authors:  Florence Folmer; Marcel Jaspars; Mario Dicato; Marc Diederich
Journal:  Biochem Pharmacol       Date:  2007-08-07       Impact factor: 5.858

2.  Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.

Authors:  J A Toretsky; Y Connell; L Neckers; N K Bhat
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels.

Authors:  Melissa Miller; Jie Shi; Yingmin Zhu; Maksym Kustov; Jin-bin Tian; Amy Stevens; Meng Wu; Jia Xu; Shunyou Long; Pu Yang; Alexander V Zholos; James M Salovich; C David Weaver; Corey R Hopkins; Craig W Lindsley; Owen McManus; Min Li; Michael X Zhu
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

4.  Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.

Authors:  Katia Scotlandi; Maria Cristina Manara; Massimo Serra; Maria Teresa Marino; Selena Ventura; Cecilia Garofalo; Marco Alberghini; Giovanna Magagnoli; Stefano Ferrari; Jose Antonio Lopez-Guerrero; Antonio Llombard-Bosch; Piero Picci
Journal:  Eur J Cancer       Date:  2011-02-21       Impact factor: 9.162

5.  Involvement of calcium in the differential induction of heat shock protein 70 by heat shock protein 90 inhibitors, geldanamycin and radicicol, in human non-small cell lung cancer H460 cells.

Authors:  Yuo-Sheng Chang; Lee-Chen Lee; Fang-Chun Sun; Chih-Chung Chao; Hua-Wen Fu; Yiu-Kay Lai
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

6.  AMPK activity is regulated by calcium-mediated protein phosphatase 2A activity.

Authors:  S Park; T L Scheffler; S S Rossie; D E Gerrard
Journal:  Cell Calcium       Date:  2013-01-05       Impact factor: 6.817

7.  Downstream EWS/FLI1 - upstream Ewing's sarcoma.

Authors:  Heinrich Kovar
Journal:  Genome Med       Date:  2010-01-28       Impact factor: 11.117

8.  EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.

Authors:  Michelle Kinsey; Richard Smith; Anita K Iyer; Edward R B McCabe; Stephen L Lessnick
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

9.  The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function.

Authors:  Noëlle Guillon; Franck Tirode; Valentina Boeva; Andrei Zynovyev; Emmanuel Barillot; Olivier Delattre
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

10.  IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.

Authors:  Luisa Cironi; Nicolò Riggi; Paolo Provero; Natalie Wolf; Mario-Luca Suvà; Domizio Suvà; Vincent Kindler; Ivan Stamenkovic
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

View more
  17 in total

1.  Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.

Authors:  Corena V Grant; Chase M Carver; Shayne D Hastings; Karthik Ramachandran; Madesh Muniswamy; April L Risinger; John A Beutler; Susan L Mooberry
Journal:  Breast Cancer Res Treat       Date:  2019-06-22       Impact factor: 4.872

Review 2.  Englerins: A Comprehensive Review.

Authors:  Zhenhua Wu; Senzhi Zhao; David M Fash; Zhenwu Li; William J Chain; John A Beutler
Journal:  J Nat Prod       Date:  2017-02-07       Impact factor: 4.050

Review 3.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

4.  Identification of an (-)-englerin A analogue, which antagonizes (-)-englerin A at TRPC1/4/5 channels.

Authors:  Hussein N Rubaiy; Tobias Seitz; Sven Hahn; Axel Choidas; Peter Habenberger; Bert Klebl; Klaus Dinkel; Peter Nussbaumer; Herbert Waldmann; Mathias Christmann; David J Beech
Journal:  Br J Pharmacol       Date:  2018-01-25       Impact factor: 8.739

5.  Tonantzitlolone is a nanomolar potency activator of transient receptor potential canonical 1/4/5 channels.

Authors:  Hussein N Rubaiy; Melanie J Ludlow; Karsten Siems; Katherine Norman; Richard Foster; Dietmar Wolf; John A Beutler; David J Beech
Journal:  Br J Pharmacol       Date:  2018-06-28       Impact factor: 8.739

6.  Na+ entry through heteromeric TRPC4/C1 channels mediates (-)Englerin A-induced cytotoxicity in synovial sarcoma cells.

Authors:  Katsuhiko Muraki; Kaori Ohnishi; Akiho Takezawa; Hiroka Suzuki; Noriyuki Hatano; Yukiko Muraki; Nurasyikin Hamzah; Richard Foster; Herbert Waldmann; Peter Nussbaumer; Mathias Christmann; Robin S Bon; David J Beech
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

Review 7.  Potential approaches to the treatment of Ewing's sarcoma.

Authors:  Hongjiu Yu; Yonggui Ge; Lianying Guo; Lin Huang
Journal:  Oncotarget       Date:  2017-01-17

8.  Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.

Authors:  Kelli L Goss; David J Gordon
Journal:  Oncotarget       Date:  2016-09-27

Review 9.  Transient receptor potential canonical 4 and 5 proteins as targets in cancer therapeutics.

Authors:  Hannah J Gaunt; Naveen S Vasudev; David J Beech
Journal:  Eur Biophys J       Date:  2016-06-11       Impact factor: 1.733

10.  Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.

Authors:  Kelli L Goss; Stacia L Koppenhafer; Kathryn M Harmoney; William W Terry; David J Gordon
Journal:  Oncotarget       Date:  2017-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.